Intelligence · Clinical Development
Pipeline search results
Programs matching “recombinant” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 118 pipeline programs matching "recombinant" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
060103
Takeda
Hemophilia A
1 trial -
061002
Takeda
Hemophilia A
1 trial -
241502
Takeda
Hemophilia A
1 trial -
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Baxalta Innovations GmbH
Hemophilia A
1 trial -
BAX 326 (Recombinant factor IX)
Takeda
Hemophilia B
1 trial -
CYD32
Sanofi Pasteur
Dengue Fever
1 trial -
Coagulation Factor VIIa (Recombinant)
Laboratoire HRA Pharma
Hemophilia
1 trial -
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Norovirus Infections
1 trial -
KLWS-V502-04
BRIGHT MINDS BIOSCIENCES INC.
Human Papillomavirus Infection
1 trial -
PEGylated Recombinant Factor VIII
Takeda
Hemophilia A
2 trials -
PEGylated Recombinant factor VIII (rFVIII)
Takeda
Hemophilia A
1 trial -
Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HPV InfectioN
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Gout
2 trials -
Recombinant Factor VIII (BAY81-8973)
Bayer HealthCare AG
Blood Coagulation Disorders
1 trial -
Recombinant Factor VIIa
United Therapeutics Europe Ltd
Burns
1 trial -
Recombinant Factor VIIa BI (rFVIIa BI)
Takeda
Hemophilia A
1 trial -
Recombinant Human Albumin Injection
The First People's Hospital of Lianyungang
Hepatic Ascites
2 trials -
Recombinant Human Thrombopoietin (rhTPO)
The First People's Hospital of Lianyungang
Immune Thrombocytopenia
1 trial -
Recombinant Human VEGF Receptor-Fc Fusion Protein
Biotech Pharmaceutical Co.,
Neovascular Age-related Macular Degeneration
1 trial -
Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Respiratory Syncytial Virus (RSV)
1 trial -
Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
Livzon Pharmaceutical Group
COVID-19 Pandemic
1 trial -
Recombinant factor IX
Takeda
Hemophilia B
1 trial -
Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
Recombinant human luteinizing hormone (r-hLH)
Merck KGaA, Darmstadt, Germany
Hypogonadism
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.